PEA does not block inflammation. It changes what the cell transcribes.

What palmitoylethanolamide is

PEA is the amide of palmitic acid (C16:0) and ethanolamine — a fatty-acid ethanolamide, structurally a close cousin of anandamide and oleoylethanolamide. It is not a plant extract, not a cannabinoid and not a synthetic drug analogue. It is a molecule the human body already makes.

Cells across essentially every tissue synthesise PEA on demand in response to injury or stress, from N-acyl-phosphatidylethanolamine precursors in the membrane, via the enzyme NAPE-PLD. It is not stored in vesicles and released; it is manufactured at the point of need and degraded locally afterwards. This is what makes it an autacoid — a local hormone whose job is to keep a tissue response proportionate.

A seventy-year history

The story starts in 1954, when Coburn and colleagues at the Rockefeller Institute noticed that dietary egg yolk protected guinea pigs against experimentally induced inflammatory arthritis. Something in the yolk was anti-inflammatory. Three years later, in 1957, a team at the Merck Institute for Therapeutic Research led by Frank Kuehl isolated and identified the responsible molecule — N-(2-hydroxyethyl)-palmitamide — and published it in the Journal of the American Chemical Society. The following year the same compound was recovered from peanut meal and soybean lecithin.

PEA then had a curious commercial life. It was marketed in Czechoslovakia from the early 1970s as Impulsin, for respiratory infection prophylaxis, and in Spain as Palmidrol from 1976. Six double-blind placebo-controlled trials were run between 1972 and 1977 across 3,627 subjects — a scale of investigation that most modern nutraceutical ingredients never approach. Then it largely disappeared, because nobody could explain how it worked.

The mechanism only arrived in 1993, when Rita Levi-Montalcini — who had shared the 1986 Nobel Prize for the discovery of nerve growth factor — and her colleagues proposed that PEA and its structural relatives were ALIAmides: autacoids synthesized locally to antagonise injury, principally by down-modulating mast cells.The ALIA hypothesis: Autacoid Local Injury Antagonism

The molecular receptor came later still. In 2005, LoVerme and colleagues demonstrated that the nuclear receptor PPAR-α mediates PEA's anti-inflammatory action, which finally gave the field a target to work against. Everything published since sits on that foundation.

PPAR-α: the primary mechanism

Peroxisome proliferator-activated receptor alpha is a ligand-activated transcription factor. PEA binds it with an EC₅₀ reported in the low micromolar range. Once bound, PPAR-α heterodimerizes with the retinoid X receptor, translocates to the nucleus, and changes which genes get transcribed.

The evidence that this is the mechanism rather than a mechanism is genetic, and it is unusually clean. In PPAR-α knockout mice — animals that cannot express the receptor at all — PEA's anti-inflammatory, analgesic and neuroprotective effects simply disappear. Co-administering a PPAR-α antagonist does the same thing in normal animals. Remove the receptor, remove the effect.

What changes downstream:

• NF-κB nuclear translocation is suppressed. NF-κB is the master switch for inflammatory gene expression; keeping it out of the nucleus is upstream of most of what follows.
• COX-2 and iNOS expression fall. Note the mechanistic distinction from an NSAID: PEA reduces how much COX-2 the cell makes, rather than inhibiting enzyme that is already present. That is a difference in mechanism, not a comparative safety claim — PEA and NSAIDs have not been compared head to head under controlled conditions.
• Pro-inflammatory cytokine output declines, TNF-α among them.

ALIA: mast cells and glia

The ALIA framework predates the receptor work and remains the best description of what PEA does at cellular level. Mast cells sit at the interface between tissue injury and the inflammatory response; when they degranulate they release histamine, prostaglandins, cytokines and nerve growth factor, sensitising nearby nociceptors. PEA restrains that degranulation. In allergen-challenged canine skin mast cells, PEA inhibited histamine, prostaglandin D₂ and TNF-α release in a dose-dependent manner across the 10⁻⁸ to 10⁻⁶ M range.

The same logic extends into the central nervous system, where microglia and astrocytes play the analogous role. Chronic pain states are increasingly understood as involving glial over-activation, and PEA down-modulates it. The distinction worth holding onto is that PEA is described in the literature as an immunomodulator rather than an immunosuppressant — it appears to restore proportionality rather than switching the response off. One paper describes PEA as enhancing microglial migration without promoting their activation, which is a rather different thing from suppression.

The entourage effect: what PEA does not do

This is where most consumer-facing content about PEA goes wrong, so it is worth being precise.

PEA does not bind CB1 or CB2 receptors to any meaningful degree. It is not a cannabinoid. It has no psychoactivity, no CB1-mediated effects, and nothing in common with THC beyond a family resemblance in the lipid class.

What it does instead is influence endocannabinoid tone indirectly, by several routes:

• FAAH competition. Fatty acid amide hydrolase degrades anandamide. PEA is also a FAAH substrate, so its presence occupies the enzyme and spares anandamide from breakdown — prolonging anandamide's own CB1 and CB2 signalling. This is the classical entourage mechanism.
• CB2 upregulation. PEA increases CB2 receptor expression as a downstream consequence of PPAR-α activation.
• 2-AG potentiation. PEA raises levels of 2-arachidonoylglycerol and potentiates its action at TRPV1 channels.

So the accurate framing is: PEA is endocannabinoid-adjacent. It modulates a system that cannabinoids act on directly. That is a genuinely useful commercial story — it explains overlapping benefit without the regulatory and psychoactivity baggage — but it should be told correctly.

TRPV1 and the sensory neuron

TRPV1 is the capsaicin receptor, a cation channel on sensory neurons that signals noxious heat and chemical irritation. PEA both activates and, importantly, desensitizes it — an effect shown to be mediated through PPAR-α. Repeated exposure leaves the channel less responsive to subsequent noxious stimuli. This is thought to contribute to the anti-nociceptive component of PEA's effect, distinct from the anti-inflammatory transcriptional arm.

What is disputed, and what is not known

Any supplier who tells you the mechanism is fully settled is either not reading the literature or hoping you are not.

Pharmacokinetics and why particle size matters

Human pharmacokinetic data on PEA is sparse. What exists points in a consistent direction.

After a 300 mg oral dose of micronized PEA in humans, plasma concentration peaked at roughly 22 pmol/mL at two hours and returned to baseline within four. In rats, ultra-micronized PEA at 30 mg/kg reached a peak of 5.4 pmol/mL at five minutes against 1.1 pmol/mL for the same dose of unmicronized material — roughly a five-fold difference driven purely by formulation. In beagles at the same dose, ultra-micronized PEA produced about a five-fold increase in blood concentration over non-micronized.

The mechanistic explanation is straightforward Noyes–Whitney dissolution behavior. PEA is highly lipophilic and practically insoluble in water. Absorption is limited by how fast the crystal dissolves in gastrointestinal fluid, and dissolution rate scales with surface area. Reduce particle size, increase surface area, increase the rate and extent of absorption.

The cleanest demonstration comes from a rat inflammatory pain model: orally, micronized and ultra-micronized PEA significantly reduced edema and hyperalgesia while unmicronized PEA did not. Given intraperitoneally — bypassing the gut entirely — all three forms worked equally well. The gap is absorption, not pharmacology.

Read the full particle-size analysis

Where PEA occurs naturally

PEA is present in the human body and in a range of foods, though at concentrations far below any therapeutic dose — you would have to eat an implausible quantity of soy lecithin to reach 400 mg.

Figures compiled from a published food-composition review. Analytical methods differ between the underlying primary studies, so treat these as indicative orders of magnitude rather than precise assays.

In the body, PEA has been detected in muscle, spleen, eye, gastrointestinal tract, spinal cord, skin, heart, blood, adipose tissue, brain and reproductive fluids. Endogenous levels change under stress and inflammation, which is precisely what an on-demand autacoid should do.